ESR1 and cancer: TNBC, characterized by the lack of an estrogen receptor, progesterone receptor, and HER2, is an extremely heterogenous and aggressive cancer that does not respond to available HER2-targeted therapies, lacks effective treatment regimens, and is associated with a high chance of metastasis and poor prognosis [74].